Acusphere to Host Conference Call to Discuss 2006 Q4 Results

Business Wire, March 8, 2007

WATERTOWN, Mass. -- Acusphere, Inc. (NASDAQ: ACUS) announced that it expects to host a conference call on Monday, March 19, 2007 at 1:00 pm ET to discuss the Company's financial results, quarterly highlights and business outlook for its fourth quarter and year ended December 31, 2006. The call will include representatives of the Company including Sherri Oberg, President and CEO and John Thero, SVP and Chief Financial Officer.

To listen to this conference call via audio webcast, please visit the Investor Relations section of the Company's website (www.acusphere.com) at least ten minutes prior to the start of the call and follow the directions there. The webcast will also be available as a replay, starting approximately one hour after the call is finished, through April 2, 2007. Alternately, to access the call via live telephone, please dial 1-866-271-6130, using confirmation code 18715564. Internationally, the call may be accessed by dialing 1-617-213-8894, using the same confirmation code.

In addition to the webcast replay, a telephone replay will be available from approximately 3:00 pm ET on March 19, 2007 through April 2, 2007. To access the replay please call 1-888-286-8010 and use the confirmation code of 37720708. Replay is also available internationally at 1-617-801-6888 using the same confirmation code, 37720708.

About Acusphere, Inc.

Acusphere (NASDAQ: ACUS) is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. Acusphere's three initial product candidates are designed to address large unmet clinical needs within cardiology, oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microspheres in a versatile manner that allows them to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, Imagify, is a cardiovascular drug in Phase 3 clinical development. For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" and "Imagify" are trademarks of Acusphere, Inc.